NTLA – intellia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: ARK Investment Management LLC
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: VANGUARD GROUP INC
Form 8-K Intellia Therapeutics, For: Jan 27
Form 8-K Intellia Therapeutics, For: Jan 09
Form 4 Intellia Therapeutics, For: Jan 05 Filed by: LEONARD JOHN M
Top News Decliners
3/13 Form 8-K Intellia Therapeutics, For: Mar 12 -17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.